Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Cash & Equivalents Over TimeContracting
Percentile Rank63
3Y CAGR+9.4%
5Y CAGR+15.7%
Year-over-Year Change
Cash on hand plus short-term liquid investments
3Y CAGR
+9.4%/yr
vs +78.9%/yr prior
5Y CAGR
+15.7%/yr
Recent deceleration
Acceleration
-69.5pp
Decelerating
Percentile
P63
Within normal range
vs 5Y Ago
2.1x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $98.90M | -20.3% |
| 2024 | $124.12M | +23.9% |
| 2023 | $100.14M | +32.6% |
| 2022 | $75.54M | -31.3% |
| 2021 | $110.02M | +130.7% |
| 2020 | $47.70M | +866.3% |
| 2019 | $4.94M | -33.1% |
| 2018 | $7.38M | -23.7% |
| 2017 | $9.67M | - |